Novartis stock heads into the open after an 11.0% slide
Published on 09/10/2026 at 08:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis stock closed sharply lower on the SIX Swiss Exchange on September 9, 2026, ending the session down about 11.0 percent in Swiss francs after a volatile trading day. The move came in a heavy-volume session that saw the share price finish near the lower end of its intraday range, while the Swiss Market Index closed about 1.6 percent lower as the index felt the impact of Novartis's large weighting.
September 9, 2026 in numbers
Novartis AG (ISIN CH0012005267) faced its worst single-session performance on record on September 9, 2026, as its shares fell roughly 11.0 percent on the SIX Swiss Exchange after a late-stage trial setback for its experimental therapy del-desiran. As Saxo Bank reported on September 9, 2026, Novartis fell as much as 11 percent and the Swiss Market Index lost about 1.6 percent because Novartis accounts for around 16 percent of the benchmark. The same report highlighted that the broader European Stoxx 600 index finished marginally lower, with healthcare stocks down about 2.3 percent, underscoring how the selloff in Novartis contributed to sector weakness.
The pressure on the shares was tied to late-stage clinical results for del-desiran in myotonic dystrophy type 1. As Yahoo Finance reported on September 9, 2026, Novartis shares tumbled about 13.9 percent in United States trading after Phase 3 results showed that del-desiran failed to significantly improve outcomes in patients with myotonic dystrophy type 1. The weakness in the United States listing mirrored the drop in the Swiss shares and added to a multi-day slide that had already been driven by setbacks in other late-stage programs, magnifying investor concern about the company’s development pipeline.
Trial fallout and sector focus today
Today, September 10, 2026, investors continue to assess the implications of the failed del-desiran study and other recent trial disappointments for Novartis’s medium-term growth and capital-allocation plans. As Seeking Alpha reported on September 9, 2026, Deutsche Bank downgraded Novartis after twin late-stage trial setbacks, contributing to a third consecutive day of share price declines and reinforcing the market’s focus on the company’s research and development execution. Against that backdrop, broader European healthcare performance and any additional commentary from analysts or the company on trial data and pipeline priorities may influence Novartis’s stock today, while movements in the Swiss Market Index will provide a benchmark for how the shares trade relative to the local market into the open.
